ACADIA Pharmaceuticals Inc ACAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACAD is a good fit for your portfolio.
News
-
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
-
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
-
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
-
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
-
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
-
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Trading Information
- Previous Close Price
- $18.55
- Day Range
- $18.55–19.21
- 52-Week Range
- $14.55–32.59
- Bid/Ask
- $18.50 / $19.09
- Market Cap
- $3.16 Bil
- Volume/Avg
- 2.4 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 62.30
- Price/Sales
- 3.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 610
- Website
- https://www.acadia.com
Comparables
Valuation
|
Metric
|
ACAD
|
VNDA
|
ITCI
|
|---|---|---|---|
Price/Earnings (Normalized) | 62.30 | 78.39 | — |
Price/Book Value | 6.80 | 0.66 | 13.07 |
Price/Sales | 3.88 | 2.00 | 15.11 |
Price/Cash Flow | 46.34 | 81.28 | — |
Price/Earnings
ACAD
VNDA
ITCI
Financial Strength
|
Metric
|
ACAD
|
VNDA
|
ITCI
|
|---|---|---|---|
Quick Ratio | 1.73 | 4.62 | 4.50 |
Current Ratio | 2.04 | 4.71 | 5.12 |
Interest Coverage | — | — | — |
Quick Ratio
ACAD
VNDA
ITCI
Profitability
|
Metric
|
ACAD
|
VNDA
|
ITCI
|
|---|---|---|---|
Return on Assets (Normalized) | 7.16% | 0.87% | −9.15% |
Return on Equity (Normalized) | 12.48% | 1.03% | −10.98% |
Return on Invested Capital (Normalized) | 7.68% | 1.02% | −13.47% |
Return on Assets
ACAD
VNDA
ITCI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xjnrwtsfz | Pzdv | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xbwzjqvg | Ryydks | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qvlfgbmbn | Ktbfvh | $118.7 Bil | |||
| Moderna Inc
MRNA
| Tmhmxcyv | Nxjf | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xmwmhffs | Nqvkcv | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lmrbrcsdl | Cntz | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Gjvlfss | Fnmyr | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jnvsvhxmt | Ttgwlvg | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rxsybmt | Ckqcn | $15.0 Bil | |||
| Incyte Corp
INCY
| Gxxwxmzx | Dmylh | $13.5 Bil |